← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2009First marketed drug
Jan 1, 2009First NDA
Jul 16, 2021Last known activity
Dec 26, 2022
Acquired by Sanofi-Aventis on Sep 8, 2021
Timeline
2000s
- Jan 1, 2009
Kadmon— Founded
2010s
- Jan 1, 2010
Three Rivers Pharmaceuticals— Acquired
2020s
- Jul 16, 2021
belumosudil— Marketing Organization
- Jul 16, 2021
belumosudil— NDA Organization
- Jul 16, 2021
belumosudil— NDA Secondary Org
- Sep 8, 2021
Sanofi-Aventis— Acquired By
Drugs by trial phase (17 distinct, 42 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Autoimmune Diseases
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Fibrosis
- Glioblastoma
- Graft vs Host Disease
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hyperlipidemias
- Hyperlipoproteinemias
- Hypertension
- Hypertriglyceridemia
- Idiopathic Pulmonary Fibrosis
- Kidney Diseases
- Liver Diseases
- Lung Neoplasms
- Meningeal Carcinomatosis
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Polycystic Kidney, Autosomal Dominant
- Polycystic Kidney, Autosomal Recessive
- Polycystic Kidney Diseases
- Psoriasis
- Pulmonary Fibrosis
- Raynaud Disease
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
Marketed drugs (4)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (42)
- NCT05567406Lead sponsorPhase 2Dec 26, 2022
- NCT05806567Lead sponsorPhase 1Jul 27, 2022
- NCT05305989Lead sponsorPhase 2Feb 23, 2022
- NCT04680975Lead sponsorPhase 2Jan 20, 2021
- NCT04735822Lead sponsorEarly Phase 1Nov 1, 2020
- NCT04242147Lead sponsorPhase 1Apr 30, 2020
- NCT04166942Lead sponsorPhase 1Jan 1, 2020
- NCT03919799Lead sponsorPhase 2Apr 30, 2019
- NCT03907540Lead sponsorPhase 1Apr 26, 2019
- NCT03640481Lead sponsorPhase 2Sep 30, 2018
- NCT03530995Lead sponsorPhase 1Apr 28, 2018
- NCT03203642Lead sponsorPhase 2Jul 29, 2017
- NCT03096080Lead sponsorPhase 1Jun 14, 2017
- NCT02841995Lead sponsorPhase 2Aug 1, 2016
- NCT02852967Lead sponsorPhase 2Aug 1, 2016
Details
- Founded
- New York, NY, US Jan 1, 2009
- First NDA
- Jul 16, 2021
- Last known activity
- Dec 26, 2022
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy